WO2015103028A1 - Au multicomponent nanomaterials and synthesis methods - Google Patents
Au multicomponent nanomaterials and synthesis methods Download PDFInfo
- Publication number
- WO2015103028A1 WO2015103028A1 PCT/US2014/072092 US2014072092W WO2015103028A1 WO 2015103028 A1 WO2015103028 A1 WO 2015103028A1 US 2014072092 W US2014072092 W US 2014072092W WO 2015103028 A1 WO2015103028 A1 WO 2015103028A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dtdtpa
- aunp
- biomolecule
- nanomaterial
- conjugate
- Prior art date
Links
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 24
- 238000001308 synthesis method Methods 0.000 title abstract description 6
- 239000002105 nanoparticle Substances 0.000 claims abstract description 36
- 239000003446 ligand Substances 0.000 claims abstract description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 36
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Inorganic materials [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 claims 1
- 239000011259 mixed solution Substances 0.000 claims 1
- 150000004662 dithiols Chemical class 0.000 abstract description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 abstract description 4
- 229960003330 pentetic acid Drugs 0.000 abstract description 3
- 239000010931 gold Substances 0.000 description 70
- 239000000562 conjugate Substances 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 28
- 229910052733 gallium Inorganic materials 0.000 description 28
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 24
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 21
- 229910052737 gold Inorganic materials 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- CKHJYUSOUQDYEN-UHFFFAOYSA-N gallium(3+) Chemical compound [Ga+3] CKHJYUSOUQDYEN-UHFFFAOYSA-N 0.000 description 14
- 150000007942 carboxylates Chemical group 0.000 description 13
- 230000021615 conjugation Effects 0.000 description 11
- 230000009920 chelation Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 101710176384 Peptide 1 Proteins 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000013522 chelant Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000001636 atomic emission spectroscopy Methods 0.000 description 5
- -1 carboxylate anions Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 5
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 235000019136 lipoic acid Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 229960002663 thioctic acid Drugs 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000724 energy-dispersive X-ray spectrum Methods 0.000 description 3
- 229940044658 gallium nitrate Drugs 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000000733 zeta-potential measurement Methods 0.000 description 3
- 238000004674 71Ga NMR spectroscopy Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 238000012565 NMR experiment Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001722 carbon compounds Chemical class 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000013170 computed tomography imaging Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000001350 scanning transmission electron microscopy Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005430 electron energy loss spectroscopy Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002258 gallium Chemical class 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002836 nanoconjugate Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 238000006464 oxidative addition reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XYYVDQWGDNRQDA-UHFFFAOYSA-K trichlorogold;trihydrate;hydrochloride Chemical compound O.O.O.Cl.Cl[Au](Cl)Cl XYYVDQWGDNRQDA-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Definitions
- a field of the invention is composite nanomaterials.
- Example applications of the invention include biomedical applications such as disease treatment and disease detection,
- Multicomponent nanomaterials combine physical and biological properties of multiple materials within a single nanoconstruct. Multicomponent nanomaterials provide unique opportunities to combine properties offered separately into a single nanoconstruct. These opportunities can expand applications of a nanomaterials, such as providing simultaneous detection and treatment of various human diseases. Combining multiple components within a single nanomaterial poses significant synthesis challenges. Many efforts to combine different materials into a single nanomaterial result in the loss of one or more desired properties of the individual materials.
- AuNP-DTDTPA has been conjugated with Gd, In, or y9m Tc, and these elements have excellent molecular imaging capabilities.
- This technique involved directed, specific molecular interactions to bind the particles to a monolayer surface.
- the surface was prepared with receptors, and Au nanoparticles covered with the matching barbituric acid receptors bound with high selectivity onto this surface by a self-assembly process mediated by multiple hydrogen bonds.
- the binding mechanism is highly specific.
- DTP A Dithiolated DTP A
- DTDTPA Dithiolated DTP A
- DTDTPA provides both soft N-donor and hard O-donor ligands.
- DTP A forms kineticaily inert and thermodynamically stable metal complexes under normal laboratory conditions, DTP A based metal chelates have shown excellent in vivo stability.
- F. N. Weizer VG "The interaction of gold with gallium arsenide”Journal of Applied Physics, 1988, 64, 4618-4623. See, C. Alric, J. Taleb, G. Le Due, C. Mandon, C. Billotey, A. Le Meur- Herland, T. Brochard, F. Vocanson, M. Janier, P. Perriat, S. Roux and O. Tillement, J Am Chem Soc, "Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging," 2008, 130, 5908
- An embodiment of the invention is a multicomponent nanomaterial comprising at least one of the following: AuNP(DTDTPA)(Ga) and AuNP(DTDTPA)(biomolecule), where DTDTPA is an amino-carboxylate ligand (diethylene triamine pentaacetic acid, DTP A) linked to the surface of the Au nanoparticle (NP) via dithiol (DT) linkage.
- DTDTPA is an amino-carboxylate ligand (diethylene triamine pentaacetic acid, DTP A) linked to the surface of the Au nanoparticle (NP) via dithiol (DT) linkage.
- Another embodiment is a multicomponent nanomaterial AuNP(DTDTPA)(Ga) with a biomolecule attached, referred to as AuNP(DTDTPA)(Ga)(biomoiecule) or AuNP(DTDTPA)(Ga)(B) wherein B stands for a biomolecule.
- Biomolecules in the present invention are any biomolecules comprising an amine group, including, but not limited to, peptides, antibodies, ScFv antibodies, the Fab portion of an antibody, affibodies, enzymes, proteins and molecules comprising an amine group.
- the Ga is Ga-67 or Ga-68. Preferred synthesis methods are conducted at room temperature.
- B is one of the following: a peptide, antibody, affibody, protein or a molecule with at least one amine group available for conjugation.
- FIG. 1 shows absorbance of conjugated HRP as a biomolecule model with serial 10 fold dilutions of AuNP(DTDTPA)(Ga);
- FIG. 2 illustrates the synthesis AuNP-(DTDTPA)fGa) and AuNP-
- DTDTPA is first conjugated with a biomolecule to produce AuNP-
- FIG. 3 shows data concerning titration of Ga(N03>3 with AuNP(DTDTPA) conjugate and the amount of Ga 3+ detected by ICP-OES and 7, Ga-NMR in terms of Au/Ga ratio and Ga + in mg, respectively;
- FIG. 4 shows 7! Ga NMR spectra of the standard solutions of Ga(N03)3 with concentrations of 0.1M, 0.01M, 0.00 i X and 0.00 1 M in D 2 0;
- FIG. 5 shows j, 1 Ga NMR spectra of the reaction supernatants of 1 with different amounts of G (N03)3;
- FIG. 6 A and FIG. 6B respectively illustrate data from in vitro stability studies of AuNP(DTDTPA) conjugate and AuNP-(DTDTPA)(Ga) under various biological media;
- FIG. 7 illustrates a preferred room temperature process for conjugation of
- FIG. 8 is an TEM image of (a) AuNP(DTDTPA)(Peptide) and (b) AuNP(DTDTPA)(Ga)(Peptide);
- FIG. 9 is in vitro stability studies of AuNP(DTDTPA)(Peptide) and (b)
- AuNP(DTDTPA)(Ga)(Peptide) by UY-Visible absorption spectroscopy (A, B); by DLS size analysis (C, D); by zeta potential ( ⁇ , F) in various biological solutions;
- FIG. 10 is (A) XPS survey spectrum of AuNP(DTDTPA)(Peptide 1): (B)
- FIG. 11 is (A) XPS hi-res spectrum of Au P(DTDTPA)(Peptide 1), S 2p
- FIG. 12 is a dose-dependent MTT cytotoxicity assay of
- An embodiment of the invention is a multicornponent nanomaterial
- DTDTPA is an amino-carboxylate ligand (diethylene triamine pentaacetic acid, DTP A) linked to the surface of the Au nanoparticle (NP) via dithiol (DT) linkage.
- Another embodiment is a multicomponent nanomaterial AuNP(DTDTPA)(Ga) with a bioniolecule attached, AuNP(DTDTPA)(Ga)(B).
- Biomolecules in the present invention are any biomolecules comprising an amine group available for conjugation, including, but not limited to, peptides, antibodies, ScFv antibodies, the Fab portion of an antibody, affihodies, enzymes, and other proteins and molecules comprising an amine group. All isotopes of Gallium are suitable in these applications. In preferred embodiments, the following isotopes of Gallium can be used: Ga-67 or Ga-68.
- the bioniolecule is attached to form a kit.
- the kit can be shipped to a health facility, and that attachment remains stable.
- Ga-67 or G-68 can be attached.
- the solution can then be administered to a patient and imaging can be conducted.
- Some embodiments include nanoconstmcts AuNP(DTDTPA)(Ga).
- B is one of the following: a peptide, antibody, affibody or a protein.
- the ratios of Au:Ga may be 1 :5; 1 :2,5 or 1 : 1 ,125, and a particular preferred embodiment has the Au:Ga ratio of about 1 :5.
- Preferred solutions of the invention include AuNP(DTDTPA)(Ga) solutions and Au P(DTDTPA)(Ga)(B) solutions having a concentration in the range of 30 ig/ml to 5 rng/ml with a pH in the range of 6 to 13.
- Au cores in the multicomponent nanomaterial have a size of -3-5 nm. Some nanoconstmcts have hydrodynam c size of 88 nm and a -55 iiiV zeta potential.
- a preferred synthesis method involves mixing Ga(NQ.3 ⁇ 4)3 (58 niM) with
- AuNP(DTDTPA) dissolved in NaOH at room temperature with continuous stirring A preferred AuNP(DTDTPA)(Ga) with a biomolecule synthesis method suspends formed AuNP(DTDTPA)(Ga) in a buffer solution.
- EDC Ethy 1-3 - [3 -dimethyl aminopropy 1] carbodiimide hy droch loride
- biomolecule conjugation can be achieved if biomolecules contain free amino groups.
- Antibodies, affibody, and proteins have free amino groups that attach with the nanoparticle in a similar fashion.
- Peptides not containing aminogroups on the other hand can be attached to AuNP- DTDTPA using thiol groups incorporated within the peptides. Thiol groups attach with gold nanoparticles on the surface.
- AuNP(DTDTPA)(Ga)j was synthesized by treating AuNP(DTDTPA) conjugate with Ga( ⁇ ' C> ; ⁇ . ⁇ at pH 8.0.
- the optimized ratio determined Au:Ga is 1 :5.
- Complex AuNP(DTDTPA)(Ga) exhibits a core size of ⁇ 3-5 nm, hydrodynamic size of 88 nm and a -55 mV zeta potential.
- Serial titrations determined the maximum concentration of gallium that can be incorporated within the nanoconstract (AuNP(DTDTPA) conjugate).
- the NMR results were val dated by performing additional experiments using ICP-OES.
- the Au/Ga ratios of the resultant conjugates were monitored after treatment of 11 mM of Au P(DTDTPA) conjugate (Au) with different amounts of Ga 3+ .
- the Au/Ga ratio becomes a constant after addition of 58 mM of Ga + .
- Ga 3+ may effectively complex with carboxylate anions and amines closer to the surface of gold.
- AuNP-DTDTPA-Ga structure was further analyzed by- using XPS measurements.
- Of particular interest is the binding of gallium to the surface ligand, DTDTPA.
- Surface bound DTDTPA is rich in disulfides, secondary amines, and carboxylates.
- the metallic alloy of Ga with Au is known at 400°C, it is unexpected in the present scenario, and the invention provides a surprising result with room temperature formation.
- the room temperature formation is advantageous to maintain desirable properties. Also the ability to attach a biomolecule at room temperature is advantageous to avoid harm to the biomolecule.
- Ga 3 can bind with thiol; however, thiols are present predominantly as disulfides in the parent nanoconstract. Such a binding would require oxidative addition of Ga 3+ across disulfide bonds, which is not feasible based on the chemistrv- of gal lium.
- N and O atoms present in the ligand is geometrically positioned to chelate with Ga.
- the N(1 S) levels showed a peak at 398.8 eV.
- AuNP(DTDTPA)(Ga) with varying amounts of Ga present in each of the two nanoconjugate samples; namely, conjugate samples obtained after treatment of AuNP(DTDTPA) conjugate with 29 mM of Ga, and other samples with the saturating amount of 58 mM.
- Low concentration of gallium was used deliberately to increase the number of free carboxyiates, while a very high amount (more than required for complete chelation) was used to utilize all possible carboxyiates present in the nanoconstract.
- the absorbance of conjugated HRP was pl otted against concentration of nanoconstruct (AuNP(DTDTPA)(Ga)) to relate the binding capabilities.
- FIG. 1 shows absorbance of conjugated HRP with serial 10 fold dilutions of
- the data can be interpreted to show that HRP is conjugated with sterically less-crowded carboxylates that are available after gallium chelation on the nanoparticie, While not necessary to practice the invention and without being bound to the theory, a theory supported by the data is that the carboxly!ates located on the surface attached DTDTPA ligand exhibit two orientational types of carboxylates; namely, those that form a compact carboxylate structure that takes part in chelation with Ga, and a second orientational type of carboxylate that are not conformationally favorable to form a therniodynamically stable metal chelate. The second kind of carboxylates is available for biomolecule conjugation.
- nanoconstruct AuNP (DTDTPA) conjugate containing DTDTPA ligand coating on the surface of AuNPs, is also non-toxic. Therefore, the minimal toxicity exhibited by AuNP(DTDTPA)(Ga) may be attributed to conjugated gallium. The lack of any noticeable toxicity of AuNP(DTDTPA) conjugate and AuNP(DTDTPA)iGa) make these n anon materials suitable for biomedical imaging.
- AuNPs gold nanoparticle
- Tetrachloroauric acid trihydrate HuC . 3! 1 0
- sodium borohydride NaBEU
- dietliylenetriaminepentacetic acid DTP A
- acetic anhydride anhydrous pyridine
- 2-aminoethanemiol hydrochloride triemylamine
- CH3COOIT Gallium nitrate
- AuNP-(DTDTPA)(Ga) may be first obtained and a biomolecule is then conjugated to the complex to produce AuNP-(DTDTPA)(Ga)(B).
- AuNP-(DTDTPA) may first be conjugated with a biomolecule to produce AuNP-(DTDTPA)(B) and Gallium is then reacted with the complex to produce AuNP- (DTDTPA)(Ga)(B).
- FIG. 3 shows titration of Ga( ⁇ ' 0 ? ⁇ . ⁇ with AuNP(DTDTPA) conjugate and the amount of Ga i+ detected by ICP-OES and 73 Ga-NMR in terms of Au/Ga ratio and Ga 3+ in rng, respectively.
- AuNP(DTDTPA) conjugate for titration using 75 Ga NMR spectroscopy, four different standard solutions of Ga(N0.3)3 with the respective concentrations, 0.1M, 0.0 IM, 0.00 IM and 0.000 IM, were prepared in D 2 0. ; 1 Ga NMR was recorded for each of these standard solutions and peak integration values were noted. It is well-known that ; 1 Ga NMR strongly depends on the symmetry of the complex.
- FIG. 4 shows 7 1 Ga NMR spectra of the standard solutions of GaCNOs with concentrations of 0. 1 M. 0.01M, 0.001M, and 0.000 i M in IhO. Through the integration of the 7, Ga NMR peaks a standard curve of the logarithmic integration was obtained for the different known solutions of GaiNC ⁇ as shown in inset.
- FIG. 5 shows 71 Ga NMR spectra of the reaction supernatants of 1 with different amounts of Gn( ⁇ 0 ?).;.
- the inset shows the amount of gallium coordinated to 1 1.36 mM [Au] in AuNP-DTDTPA at various concentrations of GafNOsb.
- reaction was stirred for 10 min at room temperature. After 10 minutes, ITRP solution (0.454 M) was added to the reaction mixture in 200 ⁇ of 0.1M MES buffer (pH 4.6) and incubated for 4 hours at room temperature with continuous stirring. Reaction mixture was centrifuged at 13500 rcf for 10 minutes at 25°C and the pellet was subsequently washed twice with IX PBS and suspended in IX PBS solution. Both the pellets and supernatants were used for perxoidase activity assay. The serial increase in absorption of nanoparticles (A.uNP-(DTDTPA)(Ga)) ⁇ HRP conjugate was monitored and correlated to the binding of HRP protein to AuNP- (DTDTPA)(Ga).
- the outer layer carboxylases in AuNP-(DTDTPA)(Ga) were activated using EDC in an activation buffer and conjugated with HRP.
- the conjugate was characterized by peroxidase assay using ELISA and also by measuring zeta potential, size, TEM and TEM with EDX.
- the EDX spectrum from a group of nanoparticles showed the presence of gold and gallium in HRP conjugated nanoconstract on a copper/carbon grid.
- the stability behavior for both were also monitored by challenging aqueous solutions of TDTPA) conjugate and AuNP-(DTDTPA)(Ga) (0.5 mL) with 0.5 mL each of 0.2M cysteine, 0.2M histidine, 0.2M HSA and 10% saline solutions.
- the stability was measured by monitoring the UV-visible absorbance, hydrodynanuc radius and zeta potential measurements at 0 hour to 96 hours (namely, at 0, 1 , 24, 48, 72, and 96 hours).
- FIG. 6A and FIG. 6B illustrate data from in vitro stability studies of AuNP(D TDTPA) conjugate and AuNP-(DTDTPA)(Ga) under various biological media of 10% NaCl, 0.5% cysteine, 0.2 M histidine, 0.5% HSA, and 0.5% BS A solutions. UV-visible absorption spectra of these solutions after 24 hours treatment were recorded.
- Nanoparticle tracking analysis was also performed on both
- AuNP(DTDTPA) conjugate and AuNP-(DTDTPA)(Ga) to confirm the structural integrity by tracking nanoparticles simultaneously moving under Brownian motion using NTA.
- the average particle size by NTA confirmed hydrodynamic diameter of -85 mil for AuNP(DTDTPA) conjugate and no major change in size was observed for conjugate AuNP-(DTDTPA)(Ga) (- ⁇ 98 nm) confirming that the structural integrity is preserved upon chelation,
- AuNP -PEG-750 (characterized independently) was treated with different ratios of Ga 3 i , The reactions were performed under identical conditions, as were utilized and followed for the preparation of AuNP-(DTDTPA)(Ga). The nanoconstructs obtained were characterized bv HR-TEM, EDX, UV- Visible, size and zeta analysis and the data were compared with AuNP- (DTDTPA)fGa).
- the second model was AuNP coated with thioctic acid (AuNP-TA).
- AuNP-TA thioctic acid
- the rationale for choosing (AuNP-TA) is as follows: (a) TA group has carboxylates outside; however, it lacks chelating ligand structures as present in DTP A. (b) TA also has size (core size 3- 5 nm), which is a size similar to that of AuNP(DTDTPA) (1), (c) Additionally the synthetic route for preparation of TA-AuNP is also similar to those of AuNP(DTDTPA). The reaction of Ga 3+ with TA-AuNP was performed under identical conditions as followed for the preparation of AuNP-(DTDTPA)(Ga). Final product was thoroughly characterized by HR-TEM, EDX, UV ⁇ Visible, size and zeta analysis and data were compared with those of AuNP-(DTDTPA)(Ga).
- AuNP-PEG (10.05 M [Au]) in different molar ratios (Au:Ga ratio; 1 :5, 1 :2.5, 1 : 1.125) and stirred for 3 hours at room temperature.
- Au:Ga ratio 1 :5, 1 :2.5, 1 : 1.125
- Gold mirror formation was observed on the walls (ES- Figure 17) within 5 minutes of gallium nitrate addition at all ratios.
- the solution was centrifuged (20,000 rcf for 20 min) after 3 hours and pellets obtained were washed three times, resuspended in DI water and used for characterization.
- FIG. 7 summarizes preferred synthesis.
- the AuNP- (DTDTPA)(Ga) is formed at room temperature.
- HRP is attached as a biomolecule model.
- the inventors have calculated that the maximum molar ratio Ga:Au that can be obtained is -1.2, which means that there is slightly more Ga in the AuNPs than Au. This is actually a plausible result if one takes into account that the Au cores are very small (3-5 nm) and the polymeric coating of DTDTPAs can coordinate considerable amount of Ga.
- the zeta potential value of 2 (-81 mV (1) to -55 mV) shows a positive shift indicating coordination of electropositi e gallium coordination.
- the inventors performed serial titrations of 1 with Ga 3+ and evaluated the resultant conj gate using both Ga ⁇ 71 NMR spectroscopy and 1CP-OES analysis (See Fig. 3).
- the NMR active 71 Ga is used as a probe to determine the concentration of chelated Ga.
- NMR. of different concentrations of Ga(N03 )3 were recorded in D20 (See Table 3).
- a standard curve using concentrations of non-chelated Ga vs. peak integration values were plotted. Using the plot, the inventors determined that 1 1 mM of Au can irreversibly chelate up to 58 mM of Ga.
- Peptide 1 Thioctic acid bombesin; Lipoic-Gln-Trp-Aia-Val-Gly-His-Leu-
- Peptide 2 ⁇ ⁇ ⁇ 1-£ ⁇ 5-£ ⁇ 8 ⁇ 8( ⁇ )- ⁇ 02- ⁇ - ⁇ 8- ⁇ - ⁇ -01 ⁇ -
- Thioctic acid terminated peptide was reacted with gold nanoparticles with stiochiometric ratios of AiuPeptide 1 :0.25, 1 :0.5, 1 : 1, 1 :2 and 1 :4.
- Thioctic acid terminated peptide [0.57 LimoL 1 .14 ⁇ , 2.27 ⁇ , 4.54 ⁇ ⁇ and 9.08 ⁇ ] were dissolved in 4 ml, of MeOH and then added to the nanoparticles solution.
- the reaction mixture was stirred for 2 hours at room temperature and formation of a dark brown precipitate was observed.
- the mixture was centrifuged (9300 g for 10 min at 20°C) and the supernatant was removed.
- the precipitated AuNPs were washed two times with MeOH and three times with water.
- the AuNP(DTDTPA)(Pe tide) were dried at low pressure and stored at -20°C.
- the collected AuNPs were diluted in 150 LiL of H20 and their radiochemical purity assessed by ITLC-SG, using 6M HCl/MeOH (5:95) as eluent (AuNP(DTDTPA)(Peptide): Rf 0).
- the radiolabeling yield was 87,5% and the radiochemical purity >95%,
- Fig. 8 is a micrograph of (a) AuNP(DTDTPA)(Peptide) and (h) Au P(DTDTPA)(Ga)(Peptide). Table 4 below provides physicochemical properties of various reactions of BB -AuNP-DTDTPA.
- Table 4 Physicochemical properties of various reactions of BBN-AuNP- DTDTPA.
- Fig. 10 provides the XPS survey spectrum of AuNP(DTDTPA)(Peptide 1 ).
- Fig. 1 1 provides the XPS hi-res spectrum of A.u P(DTDTPA)(Peptidel).
- Table 5 reports the relative elemental composition for
- AuNP(DTDTPA)iPeptide l) "able 5; Relative Elemental Composition of AuDTBBN-NPs as Determined by GPS [Atom %]
- Table 6 report relative compositions and most probable peak assignments for carbon species.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
A multicomponent nanomaterial AuNP(DTDTPA)(Ga), where DTDTPA is an amino-carboxylate ligand (diethylene triamine pentaacetic acid, DTPA) linked to the surface of the Au nanoparticle (NP) via dithiol (DT) linkage. Another embodiment is a multicomponent nanomaterial AuNP(DTDTPA)(Ga) with a biomolecule attached. In preferred embodiments, the Ga is Ga-67 or Ga-68. Preferred synthesis methods are conducted at room temperature.
Description
AU MULTICOMPONENT
NANOMATERIALS AND SYNTHESIS METHODS
PRIORITY CLAIM AND REFERENCE TO RELATED APPLICATION
[001] The application claims priority under 35 U.S.C. § 119 from prior provisional application serial number 61/964,285, which was filed December 30, 2013.
FIELD
[002] A field of the invention is composite nanomaterials. Example applications of the invention include biomedical applications such as disease treatment and disease detection,
BACKGROUND
[003] Multicomponent nanomaterials combine physical and biological properties of multiple materials within a single nanoconstruct. Multicomponent nanomaterials provide unique opportunities to combine properties offered separately into a single nanoconstruct. These opportunities can expand applications of a nanomaterials, such as providing simultaneous detection and treatment of various human diseases. Combining multiple components within a single nanomaterial poses significant synthesis challenges. Many efforts to combine different materials into a single nanomaterial result in the loss of one or more desired properties of the individual materials.
[004] AuNP-DTDTPA has been conjugated with Gd, In, or y9mTc, and these elements have excellent molecular imaging capabilities. R. Zirbs, F. Kienberger, P. Hinterdorfer and W. H. Binder, Langmuir, "Directed assembly of Au nanoparticies onto planar surfaces via multiple hydrogen bonds," 21, 8414-8421 (2005). This technique involved directed, specific molecular interactions to bind the particles to a monolayer surface. The
surface was prepared with receptors, and Au nanoparticles covered with the matching barbituric acid receptors bound with high selectivity onto this surface by a self-assembly process mediated by multiple hydrogen bonds. The binding mechanism is highly specific. Dithiolated DTP A (DTDTPA) provides both soft N-donor and hard O-donor ligands. Unlike other N, O- ligands, DTP A forms kineticaily inert and thermodynamically stable metal complexes under normal laboratory conditions, DTP A based metal chelates have shown excellent in vivo stability. F. N. Weizer VG, "The interaction of gold with gallium arsenide"Journal of Applied Physics, 1988, 64, 4618-4623. See, C. Alric, J. Taleb, G. Le Due, C. Mandon, C. Billotey, A. Le Meur- Herland, T. Brochard, F. Vocanson, M. Janier, P. Perriat, S. Roux and O. Tillement, J Am Chem Soc, "Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging," 2008, 130, 5908-5915.
SUMMARY OF THE INVENTION
05] An embodiment of the invention is a multicomponent nanomaterial comprising at least one of the following: AuNP(DTDTPA)(Ga) and AuNP(DTDTPA)(biomolecule), where DTDTPA is an amino-carboxylate ligand (diethylene triamine pentaacetic acid, DTP A) linked to the surface of the Au nanoparticle (NP) via dithiol (DT) linkage. Another embodiment is a multicomponent nanomaterial AuNP(DTDTPA)(Ga) with a biomolecule attached, referred to as AuNP(DTDTPA)(Ga)(biomoiecule) or AuNP(DTDTPA)(Ga)(B) wherein B stands for a biomolecule. Biomolecules in the present invention are any biomolecules comprising an amine group, including, but not limited to, peptides, antibodies, ScFv antibodies, the Fab portion of an antibody, affibodies, enzymes, proteins and molecules comprising an amine group. In preferred embodiments, the Ga is
Ga-67 or Ga-68. Preferred synthesis methods are conducted at room temperature.
[006] Further embodiments include the nanoconstruct AuNP(DTDTPA)(Ga)(B);
wherein B is one of the following: a peptide, antibody, affibody, protein or a molecule with at least one amine group available for conjugation.
BRIEF DESCRIPTION OF THE DRAWINGS
[007] FIG. 1 shows absorbance of conjugated HRP as a biomolecule model with serial 10 fold dilutions of AuNP(DTDTPA)(Ga);
[008] FIG. 2 illustrates the synthesis AuNP-(DTDTPA)fGa) and AuNP-
(DTDTPA)(Ga)(B), wherein B is a biomolecule. In Fig. 2A. AuNP-
(DTDTPA)(Ga) is first obtained and a biomolecule is then conjugated to the complex to produce AuNP-(DTDTPA)(Ga)(B). In Fig. 2B, AuX P-
(DTDTPA) is first conjugated with a biomolecule to produce AuNP-
(DTDTPA)(B) and Gallium is then reacted with the complex to produce
AuNP-(DTDTPA)(Ga)(B);
[009] FIG. 3 shows data concerning titration of Ga(N03>3 with AuNP(DTDTPA) conjugate and the amount of Ga3+ detected by ICP-OES and 7,Ga-NMR in terms of Au/Ga ratio and Ga + in mg, respectively;
[0010] FIG. 4 shows 7!Ga NMR spectra of the standard solutions of Ga(N03)3 with concentrations of 0.1M, 0.01M, 0.00 i X and 0.00 1 M in D20;
[001 1] FIG. 5 shows j, 1Ga NMR spectra of the reaction supernatants of 1 with different amounts of G (N03)3;
[00 2] FIG. 6 A and FIG. 6B respectively illustrate data from in vitro stability studies of AuNP(DTDTPA) conjugate and AuNP-(DTDTPA)(Ga) under various biological media; and
[0013] FIG. 7 illustrates a preferred room temperature process for conjugation of
AuNP-(DTDTPA)(Ga) and AuNP-(DTDTPA)(Ga)ITRP;
FIG. 8 is an TEM image of (a) AuNP(DTDTPA)(Peptide) and (b) AuNP(DTDTPA)(Ga)(Peptide);
[0015] FIG. 9 is in vitro stability studies of AuNP(DTDTPA)(Peptide) and (b)
AuNP(DTDTPA)(Ga)(Peptide) by UY-Visible absorption spectroscopy (A, B); by DLS size analysis (C, D); by zeta potential (Έ, F) in various biological solutions;
[0016] FIG. 10 is (A) XPS survey spectrum of AuNP(DTDTPA)(Peptide 1): (B)
XPS hi -res spectrum of AuNP(DTDTPA)(Peptide 1), C Is Region;
[0017] FIG. 11 is (A) XPS hi-res spectrum of Au P(DTDTPA)(Peptide 1), S 2p
Region; (B) XPS hi-res spectrum of AuNP(DTDTPA)(Peptide 1), Au 4f Region; and
[0018] FIG. 12 is a dose-dependent MTT cytotoxicity assay of
AuNP(DTDTPA)(Peptide 1) ( 1 :2) in PC-3 prostate cancer cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] An embodiment of the invention is a multicornponent nanomaterial
AuNP(DTDTPA)(Ga) or AuNP(DTDTPA)(Biomolecule), where DTDTPA is an amino-carboxylate ligand (diethylene triamine pentaacetic acid, DTP A) linked to the surface of the Au nanoparticle (NP) via dithiol (DT) linkage. Another embodiment is a multicomponent nanomaterial AuNP(DTDTPA)(Ga) with a bioniolecule attached, AuNP(DTDTPA)(Ga)(B). Biomolecules in the present invention are any biomolecules comprising an amine group available for conjugation, including, but not limited to, peptides, antibodies, ScFv antibodies, the Fab portion of an antibody, affihodies, enzymes, and other proteins and molecules comprising an amine group. All isotopes of Gallium are suitable in these applications. In preferred embodiments, the following isotopes of Gallium can be used: Ga-67 or Ga-68.
[0020] Strong attachments are formed. In preferred embodiments, the bioniolecule is attached to form a kit. The kit can be shipped to a health facility, and that
attachment remains stable. At the health facility, with the room temperature mixing of preferred formation methods, Ga-67 or G-68 can be attached. The solution can then be administered to a patient and imaging can be conducted.
[0021] Some embodiments include nanoconstmcts AuNP(DTDTPA)(Ga).
[0022] Further embodiments include the nanoconstract AuNP(DTDTPA)(Ga)(B);
wherein B is one of the following: a peptide, antibody, affibody or a protein.
[0023] The ratios of Au:Ga may be 1 :5; 1 :2,5 or 1 : 1 ,125, and a particular preferred embodiment has the Au:Ga ratio of about 1 :5. Preferred solutions of the invention include AuNP(DTDTPA)(Ga) solutions and Au P(DTDTPA)(Ga)(B) solutions having a concentration in the range of 30 ig/ml to 5 rng/ml with a pH in the range of 6 to 13. In preferred embodiments, Au cores in the multicomponent nanomaterial have a size of -3-5 nm. Some nanoconstmcts have hydrodynam c size of 88 nm and a -55 iiiV zeta potential.
[0024] A preferred synthesis method involves mixing Ga(NQ.¾)3 (58 niM) with
AuNP(DTDTPA) dissolved in NaOH at room temperature with continuous stirring. A preferred AuNP(DTDTPA)(Ga) with a biomolecule synthesis method suspends formed AuNP(DTDTPA)(Ga) in a buffer solution. 1- Ethy 1-3 - [3 -dimethyl aminopropy 1] carbodiimide hy droch loride (EDC) is added and stirred. Subsequently, a biomolecule in solution is added and continuously stirred and incubated at room temperature for a time period.
[0025] Preferred embodiments of the invention will now be discussed with respect to experiments. The experiments illustrate broader aspects of the invention, as will be appreciated by artisans.
[0026] In experiments to demonstrate the invention, methods provided synthesis of
[AuNP(DTDTPA)(Ga)] , characterization of AuNP(DTDTPA)(Ga) using advanced scanning transmission electron microscopy (STEM) techniques; detailed in vitro stability and cytotoxicity studies of A.uNP(DTDTPA.)(Ga); and syn thesis and characterization of [AuNP(DTDTPA)(Ga)(HRP)], as a
model for hiomolecule attachment. HRP (horseradish peroxidase) has six primary amine residues (lysine), which are available for effective conjugation. (K.G. Welinder, Covalent structure of the glycoprotein horseradish peroxidase (EC 1.1 1.1.7). 1976, FEBS Lett.72, 19-23). In general, biomolecule conjugation can be achieved if biomolecules contain free amino groups. Antibodies, affibody, and proteins have free amino groups that attach with the nanoparticle in a similar fashion. Peptides not containing aminogroups on the other hand, can be attached to AuNP- DTDTPA using thiol groups incorporated within the peptides. Thiol groups attach with gold nanoparticles on the surface.
[0027] The experiments showed that layered carboxylate structure plays an important role for attachment. The experiments confirmed that the multilayered carboxylate architecture is fairly stable over a wride range of pH (6 to 13) and at different concentrations (30 ig/ml to 5 rng/ml),
[0028] [AuNP(DTDTPA)(Ga)j was synthesized by treating AuNP(DTDTPA) conjugate with Ga( \'C> ;}.< at pH 8.0. The optimized ratio determined Au:Ga is 1 :5. Complex AuNP(DTDTPA)(Ga) exhibits a core size of ~3-5 nm, hydrodynamic size of 88 nm and a -55 mV zeta potential. Serial titrations determined the maximum concentration of gallium that can be incorporated within the nanoconstract (AuNP(DTDTPA) conjugate). Specifically, serial titrations of AuNP(DTDTPA) conjugate with Ga3+ were performed and evaluated the resultant conjugate using both Ga-71 NMR spectroscopy and IC-P-OES analysis. The NMR active /!Ga is used as a probe to determine the concentration of chelated Ga. NMR of different concentrations of Ga(N€> )3 were recorded in D2O. A standard curve using concentrations of nori- chelated Ga vs. peak integration values were plotted. Using the plot, it was determined that 11 mM of Au can irreversibly chelate up to 58 mM of Ga. These results indicate any gallium added beyond this concentration would not be chelated with AuNP-DTDTPA.
1002 1 The NMR results were val dated by performing additional experiments using ICP-OES. In this experiment, the Au/Ga ratios of the resultant conjugates were monitored after treatment of 11 mM of Au P(DTDTPA) conjugate (Au) with different amounts of Ga3+. The Au/Ga ratio becomes a constant after addition of 58 mM of Ga +. These experiments establish the exact concentration of Ga that can be irreversibly chelated to AuNP(DTDTPA) conjugate. The smaller core size of AuNP(DTDTPA)(Ga) made the characterization quite challenging.
[0030] Multiple analytical tools (UV-Vis, TEM, DLS, XPS, EDX, HAADF, and
EELS) were used to obtain structural details of Au P(DTDTPA)(Ga). Conventional techniques such as UV-Vis and TEM confirmed that the crystallinity of gold core AuNP(DTDTPA) conjugate is retained after chelation with Ga. As the gold core size is less than 5 nm, the surface plasmon resonance showed a small hump at 520 nm before and after complexation.
[003 1 ] Ga3+ may effectively complex with carboxylate anions and amines closer to the surface of gold. AuNP-DTDTPA-Ga structure was further analyzed by- using XPS measurements. Of particular interest is the binding of gallium to the surface ligand, DTDTPA. Surface bound DTDTPA is rich in disulfides, secondary amines, and carboxylates. Even though the metallic alloy of Ga with Au is known at 400°C, it is unexpected in the present scenario, and the invention provides a surprising result with room temperature formation. The room temperature formation is advantageous to maintain desirable properties. Also the ability to attach a biomolecule at room temperature is advantageous to avoid harm to the biomolecule.
[0032] It is possible that Ga3 : can bind with thiol; however, thiols are present predominantly as disulfides in the parent nanoconstract. Such a binding would require oxidative addition of Ga3+ across disulfide bonds, which is not feasible based on the chemistrv- of gal lium. However, N and O atoms present
in the ligand is geometrically positioned to chelate with Ga. In the conjugate AuNP(DTDTPA)iGa), the N(1 S) levels showed a peak at 398.8 eV.
Having established the synthesis and characterization of [AuNP(DTDTPA)Ga] (2) conjugate, the inventors focused our attention to explore further utilization of carboxylate ligands on AuNP(DTDTPA)(Ga) for conjugating with biomoiecules. For proving the concept that such conjugation was feasible, the inventors used HRP (horseradish peroxidase) as a biomolecule. The inventors conjugated HRP to AuNP(DTDTPA)(Ga) to demonstrate this biomolecule was successfully conjugated to Au P(DTDTPA)(Ga). Presence of HRP was detected by conventional ELISA technique. The inventors utilized two different conjugates of
AuNP(DTDTPA)(Ga), with varying amounts of Ga present in each of the two nanoconjugate samples; namely, conjugate samples obtained after treatment of AuNP(DTDTPA) conjugate with 29 mM of Ga, and other samples with the saturating amount of 58 mM. Low concentration of gallium (less than required for complete chelation) was used deliberately to increase the number of free carboxyiates, while a very high amount (more than required for complete chelation) was used to utilize all possible carboxyiates present in the nanoconstract. The absorbance of conjugated HRP was pl otted against concentration of nanoconstruct (AuNP(DTDTPA)(Ga)) to relate the binding capabilities.
FIG. 1 shows absorbance of conjugated HRP with serial 10 fold dilutions of
AuNP(DTDT A)(Ga). The absorbance increases with increasing concentration of AuNP(DTDTPA)(Ga) as the HRP holding capability of Au P(DTDTPA)(Ga) increases. On the other hand, chelates with varying concentrations of Ga (29 mM and 58 mM) did not show any difference in conjugation with HRP (inset). These data shows that HRP conjugation writh Au P(DTDTPA)(Ga) is independent of amount of chelated Ga.
[0035] The data can be interpreted to show that HRP is conjugated with sterically less-crowded carboxylates that are available after gallium chelation on the nanoparticie, While not necessary to practice the invention and without being bound to the theory, a theory supported by the data is that the carboxly!ates located on the surface attached DTDTPA ligand exhibit two orientational types of carboxylates; namely, those that form a compact carboxylate structure that takes part in chelation with Ga, and a second orientational type of carboxylate that are not conformationally favorable to form a therniodynamically stable metal chelate. The second kind of carboxylates is available for biomolecule conjugation. The possibility of interaction of gallium atoms with the conformationally unfavorable carboxylates is minimal. Due to this binding preference of gallium and HRP, the HRP conjugation efficiency remains the same for both low (29 mM) and high (58 mM) gallium chelated AuNP.
[0036] The cytotoxicity of AuNP(DTDTPA) conjugate and AuNP(DTDTPA)(Ga) was studied on human prostate cancer (PC-3) cells under in vitro conditions using a colorimetric cell-viability (MTT) assay. The results demonstrate that nanoconstructs AuNP(DTDTPA) conjugate and AuNP(DTDTPA)(Ga) do not show cytotoxicity up to 40 .iig/mL concentrations. Nevertheless, the cell viability was slightly lesser for AuNP(DTDTPA)(Ga) than AuNP(DTDTPA) conjugate for die period of 24 h post treatment. The AuNP are themselves non-toxic. In addition, the experiments showed that nanoconstruct AuNP (DTDTPA) conjugate, containing DTDTPA ligand coating on the surface of AuNPs, is also non-toxic. Therefore, the minimal toxicity exhibited by AuNP(DTDTPA)(Ga) may be attributed to conjugated gallium. The lack of any noticeable toxicity of AuNP(DTDTPA) conjugate and AuNP(DTDTPA)iGa) make these n anon materials suitable for biomedical imaging.
[0037] Experimental Materials
[0038] The materials used for synthesis of gold nanoparticle (AuNPs) were procured commercially. Tetrachloroauric acid trihydrate (HAuC . 3! 1 0 ). sodium borohydride (NaBEU), dietliylenetriaminepentacetic acid (DTP A), acetic anhydride, anhydrous pyridine, 2-aminoethanemiol hydrochloride, triemylamine, glacial acetic acid (CH3COOIT), Gallium nitrate (Gn( X( ) ·■, } < }. sodium hydroxide (NaOH), hydrocloric acid (HC1), methanol (MeOH), diethyl ether (Et2Q), sodium chloride (NaCl), dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), histidine, human serum albumin (ITSA), bovine serum albumin (BSA), and cysteine were purchased from Aldrich Chemical, USA and used as received. For the preparation of aqueous solutions and for rinsing of gold nanoparticles, Milli-Q (DI) water ( > 18M ) was used. Synthesis of AuNP(DTDTPA) conjugate was performed by previously reported protocol. See, C. Alric, J. Taleb, G. Le Due, C. Mandon, C. Billotey, A. Le Meur-Herland, T. Brochard, F. Vocanson, M. Janier, P. Perriat, S. Roux and O. Tillement, J Am C em Soc, "Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging," 2.008, 130, 5908-5915. MTT Cell Proliferation Assay kit was obtained from Promega Corporation, USA,
[0039] Synthesis of Au P-(DTDTPA)(Ga)
[0040] Aqueous solution of Ga( \( ) ;).? (58 mM) was mixed with AuNP(DTDTPA) conjugate (1 1.36mM of [Au]) dissolved in 0.01 M NaOH at room temperature with continuous stirring. Immediate precipitate formation was observed. The reaction mixture was allowed to stir for 3 hours and subsequently washed with DI water (three times) and centrifuged at 20000 rcf for 20 rains at 25°C. rcf is relative centrifugal force, and corresponds to the force associated with 1 g, where g is the acceleration of gravity at the surface of the Earth. FIG. 2 illustrates the synthesis AuNP-(DTDTPA)(Ga), Au P-PEG+Ga, TA-AuNP+Ga with respective HR-TEM and EDX Spectra confirming the presence and absence of Ga cations. As shown in Fig. 2A,
AuNP-(DTDTPA)(Ga) may be first obtained and a biomolecule is then conjugated to the complex to produce AuNP-(DTDTPA)(Ga)(B). Alternatively and as shown in Fig. 2B, AuNP-(DTDTPA) may first be conjugated with a biomolecule to produce AuNP-(DTDTPA)(B) and Gallium is then reacted with the complex to produce AuNP- (DTDTPA)(Ga)(B).
[0041 ] Analysis of AuNP-(DTDTP A)(Ga)
[0042] To a solution of Au P(DTDTPA) conjugate (11.36 mM of [Au]) dissolved in 0.01M NaOH, a solution of increasing amounts of Ga(NOa)3 (3.9, 9.7, 1.9.5, 39, 58, 78, 117, 156 niM) in DI water was added. The chelated product was isolated. 1 mg/ml of the dried pellet (dissolved in 0.0 IM NaOH) and respective supernatants were used for ICP analysis. All measurements were performed in triplicates. To evaluate concentration of Ga that are irreversibly chelated to AuNP(DTDTPA) conjugate, the inventors determined the concentrations of [Ga] and [Au] in AuNP-(DTDTPA)(Ga). Based on ICP- OES analysis, it was evident that Au/Ga ratio remains constant be)¾nd 58 niM concentration of [Ga].
[0043] 71Ga NMR Spectroscopy
[0044] FIG. 3 shows titration of Ga( \'0 ?}.< with AuNP(DTDTPA) conjugate and the amount of Gai+ detected by ICP-OES and 73Ga-NMR in terms of Au/Ga ratio and Ga3+ in rng, respectively. For titration using 75Ga NMR spectroscopy, four different standard solutions of Ga(N0.3)3 with the respective concentrations, 0.1M, 0.0 IM, 0.00 IM and 0.000 IM, were prepared in D20. ; 1Ga NMR was recorded for each of these standard solutions and peak integration values were noted. It is well-known that ; 1Ga NMR strongly depends on the symmetry of the complex. If the gallium containing complex lacks symmetry, the NMR signal disappears. Various concentrations of G i VO. M (29.3 mM; 58.6 mM or 1 17 mM) were added to aqueous solutions of AuNP(DTDT A) conjugate (5 mg/mL). After stirring for 3 hours, the
reaction mixtures were centrifuged (20,000 rcf, 20 min, 25°C) and the supernatants decanted and concentrated to 1 niL volume. Supernatant solutions were analyzed and peak integration values were used to calculate the amount of gallium present [Peak integration and concentrations of [Ga] were standardized by a separate experiment (see FIG. 3). The slope of the straight line in the graph was a best fit to the data, and corresponded to the amount of gallium that can be coordinated to AuNP(DTDT A) conjugate (5 nig). By this NMR experiment, it is clear that 11.36 mM of [Au] in AuNP(DTDTPA) conjugate requires at least 58 mM of [Ga]. FIG. 4 shows 71 Ga NMR spectra of the standard solutions of GaCNOs with concentrations of 0. 1 M. 0.01M, 0.001M, and 0.000 i M in IhO. Through the integration of the 7,Ga NMR peaks a standard curve of the logarithmic integration was obtained for the different known solutions of GaiNC ^ as shown in inset. It should be noted that the integrations were done considering the integration value of 100 to be associated with the highest concentrated solution of i n'U '\i),: (0.1M). FIG. 5 shows 71Ga NMR spectra of the reaction supernatants of 1 with different amounts of Gn( \0 ?).;. The inset shows the amount of gallium coordinated to 1 1.36 mM [Au] in AuNP-DTDTPA at various concentrations of GafNOsb.
[0045] Synthesis of Conjugates of AuNP-(DTDTP A)(G a)
[0046] Two different conjugates of AuNP-(DTDTPA)(Ga) differing in gallium ion concentrations were synthesized. The gallium chelated gold nanoparticles, AuNP-(DTDTPA)(Ga) ([Au] = 11.36 mM and [Ga] = 29.32 mM and 58.0 mM), were suspended in IX PBS. To 500 u l of AuNP-(DTDTPA.)(Ga), 28 lig of 1 -Ethyl-3-[3-dittiethylaniinopropyl]carbodiimide hydrochloride (EDC) was added in 0.1 M
sulfonic acid (MES) buffer (pH 4.6). The reaction was stirred for 10 min at room temperature. After 10 minutes, ITRP solution (0.454 M) was added to the reaction mixture in 200 μΐ of 0.1M MES buffer (pH 4.6) and incubated for 4 hours at room
temperature with continuous stirring. Reaction mixture was centrifuged at 13500 rcf for 10 minutes at 25°C and the pellet was subsequently washed twice with IX PBS and suspended in IX PBS solution. Both the pellets and supernatants were used for perxoidase activity assay. The serial increase in absorption of nanoparticles (A.uNP-(DTDTPA)(Ga))~HRP conjugate was monitored and correlated to the binding of HRP protein to AuNP- (DTDTPA)(Ga). The outer layer carboxylases in AuNP-(DTDTPA)(Ga) were activated using EDC in an activation buffer and conjugated with HRP. The conjugate was characterized by peroxidase assay using ELISA and also by measuring zeta potential, size, TEM and TEM with EDX. The EDX spectrum from a group of nanoparticles showed the presence of gold and gallium in HRP conjugated nanoconstract on a copper/carbon grid.
[0047] Peroxidase Activity Assay Using ELISA
[0048] In a 96-well plate, 100 μ! of 3 was added in the first row and serial 10 fold dilutions of the samples were made along each column using IX PBS. To all the wre!!s was added 50 uL of TMB (3, 3\ 5, 5'-Tetra Methyl Benzidine) and one component of substrate was added. The plate was incubated at room temperature for 5 minutes and further the activity of the enzyme was stopped by addition of 50 μΕ of 1M HC1. The absorbance of the individual wells was recorded on a microplate reader at 450 run immediately. The ELISA studies were representative measurements from triplicates, and the readings were plotted as a graph of mass (in units of ng) of particles versus absorbance. HRP was used traditionally as a labeling agent for C-ierminal of various proteins, and presence of HRP wras analyzed via coupled enzyme assays.
[0049] In Vitro Stability
[0050] In vitro stability studies were performed by incubating solutions of
AuNP(DTDTPA) conjugate and A.uNP-(DTDTPA)(Ga) at various pH conditions: 2, 5, 7, 10 and 12 for the period of 24 hours. The stability behavior for both were also monitored by challenging aqueous solutions of
TDTPA) conjugate and AuNP-(DTDTPA)(Ga) (0.5 mL) with 0.5 mL each of 0.2M cysteine, 0.2M histidine, 0.2M HSA and 10% saline solutions. The stability was measured by monitoring the UV-visible absorbance, hydrodynanuc radius and zeta potential measurements at 0 hour to 96 hours (namely, at 0, 1 , 24, 48, 72, and 96 hours). A negligible change in UV-Vis piasmon band of Au P(DTDTPA) conjugate and AuNP- (DTDTPA)(Ga) confirmed the retention of nanoparticulate composition with stable behavior in all the challenging solutions except cysteine. The treated solutions did not show any noticeable change in hydrodynamic radii, thus confirming the stability of these conjugates. FIG. 6A and FIG. 6B, respectively, illustrate data from in vitro stability studies of AuNP(D TDTPA) conjugate and AuNP-(DTDTPA)(Ga) under various biological media of 10% NaCl, 0.5% cysteine, 0.2 M histidine, 0.5% HSA, and 0.5% BS A solutions. UV-visible absorption spectra of these solutions after 24 hours treatment were recorded.
[005 1 ] Characterization of AuNPi DTDTPA) Conjugate
[0052] The core size of AuNP(DTDTPA) conj ugate that showed the hydrodynamic diameter of 88 nm as observed by DLS measurements was 2-3 nm as observed from TEM images. This result validates the preservation of multi- layered structure of DTDTPA on AuNP surface. Any disturbance to H- bonding network would result in destabilization of DTDTPA structural motif and these disturbances would arise from pH variations and dilutions. The changes in hydrodynamic diameter and zeta potential due to pH and dilutions have been monitored by DLS measurements.
[0053] Effect of pH
[0054] The experiment was performed on the pH range from 2 - 13. A strong dependence of size with pH variation was observed. This dependence is shown in Table 1. At lower pH (pH 2) the size was 2417 nm. This hydrodynamic size increase is attributed to the protonation of-COOH groups
at low pH resulting in aggregation of nanoparticles. At pH 4, a decrease in size to -213 nm was observed due to decreased protonation. However, within a H range of 6 - 13, the hydrodynamic diameters of AuNP(DTDTPA) conjugate remained constant at 78±4 nm, thus ensuring that the layered structure is intact and stable in this pH range.
Table 1 - Size analysis and zeta potential measurements of 1 at standard pH buffer solutions
Cone, of pH Cone Size by DLS Zeta Potential Observations
1 (mg/ml) of Au (nm) (mV)
(niM) Mean Std Mean Std
dev dev
0.50 2 1.16 2417 315 19 1.06 Suspension
0.50 4 1.16 213 1.60 -32 1.41 Partially Soluble
0.50 5 1.16 212 1.60 -40 0.28 Partially Soluble
0.50 6 1.16 76 0.39 -33 2.90 Soluble (Clear Solution)
0.50 9 1.16 82 1.00 -54 0.14 Soluble (Clear Solution)
0.50 11 1.16 78 1.17 -53 0.98 Soluble (Clear Solution)
0.50 13 1.16 74 0.62 -48 2.60 Soluble (Clear Solution)
[0056] Effect of Dilution
[0057] The inventors also studied the effect of dilution on the layered structure of
Au P(DTDTPA) conjugate using DLS. The data are shown in Table 2. With increased concentration of AuNP(DTDTPA) conjugate, from 0.3 mg/mL (Au = 0.05 niM) to 5 mg/mL (Au = 11 ,36 mM) in Dl water at pH 8 - 8.5, no change in hydrodynamic size (average particle size :::: 88 · 4 nm) or zeta potential (average zeta potential :::: -72 mV) was observed.
I1 able 2. Size analysis and Zeta potential measurements of 1 at various dilutions
Cone, of Dilution Cone of pH Size by DLS Zeta Potential Size
Mean Std Mean Std (nm) dev dev
0.03 5ul of stock 0.050 7.80 92 2.14 -70 0.78 ND
0.05 lOul of stock 0.101 8.18 88 0.16 -80 0.49 ND
0.13 25ul of stock 0.303 7.92 90 1.05 0.21 77
0.25 5 Qui of stock 0.555 7.91 90 0.85 -79 4.73 98
0.50 lOOul of stock 1.16 8.53 88 0.65 -71 0.21 63
LOO 2Q0ul of stock 8.73 84 0.3 -68 0.49 102
LOO 2Q0ui of stock 2.27 8.73 84 Q.42 -65 2.96 ND
- recorded
after 241i
5.00 Stock Solution 11.36 - 126 2.08 NM - NM
[0058] ND : Not Determined;
[0059] Characterization of AuNP-(DTDTPA)(Ga)
[0060] To understand the effect of Ga chelation on the layered structure, the
inventors performed a detailed DLS study using the Ga chelated conjugate AuNP-(DTDTPA)(Ca) in pH 8. If some of the carboxylate anions in AuNP(DTDTPA) conjugate will complex with Ga3+ ions, the resultant negative charge will be relatively less than the parent construct. The zeta potential of AuNP-(DTDTPA)(Ga) is -55mV (-81 mV for AuNP(DTDTPA) conjugate) and the difference is -25m V, suggesting the presence of free carboxylic groups and also confirming the layered structure even after chelation. The TEM images of AuNP-(DTDTPA)(Ga) also clearly indicated that the rianoparticies are arranged in a cluster of several rianoparticies. It is
expected that a cluster of 50-60 nanoparticles interact through macro molecular H-bonding. Such H-borsding network between nanoparticulate structures is not unusual, Further, as Ga ions surround AuNP, another layer of carboxylate is available to form conjugation with biomolecule. This experiment confirmed that the structural integrity of multilayer carboxylates present in the parent AuNP(DTDTPA) conjugate is retained.
[0061 ] Nanoparticle Tracking Analysis (NT A)
[0062] Nanoparticle tracking analysis (NTA) was also performed on both
AuNP(DTDTPA) conjugate and AuNP-(DTDTPA)(Ga) to confirm the structural integrity by tracking nanoparticles simultaneously moving under Brownian motion using NTA. The average particle size by NTA confirmed hydrodynamic diameter of -85 mil for AuNP(DTDTPA) conjugate and no major change in size was observed for conjugate AuNP-(DTDTPA)(Ga) (-■98 nm) confirming that the structural integrity is preserved upon chelation,
[0063 ] Invest! gati on of Ga3+ B in ding on AuNPs
[0064] Systematic experiments have been performed to confirm the chelation of gallium atoms with DTDTPA and not present on the surface of AuNPs. To understand whether the gold nanoparticle surface has affinity towards Ga. + ions, two different "model" gold nanoparticles were chosen.
[0065] The first model AuNP that the inventors chose was AuNP coated with thiolated PEG-750 (AuNP-PEG- 750), wherein, the charge (zeta potential) of AuNP ( = -49 mV) is similar to that of AuNP(DTDTPA) ( = -81 mV) but does not contain any chelating ligand such as DTDTPA on the suriace. AuNP -PEG-750 (characterized independently) was treated with different ratios of Ga3 i , The reactions were performed under identical conditions, as were utilized and followed for the preparation of AuNP-(DTDTPA)(Ga). The nanoconstructs obtained were characterized bv HR-TEM, EDX, UV-
Visible, size and zeta analysis and the data were compared with AuNP- (DTDTPA)fGa).
[0066] The second model was AuNP coated with thioctic acid (AuNP-TA). The rationale for choosing (AuNP-TA) is as follows: (a) TA group has carboxylates outside; however, it lacks chelating ligand structures as present in DTP A. (b) TA also has size (core size 3- 5 nm), which is a size similar to that of AuNP(DTDTPA) (1), (c) Additionally the synthetic route for preparation of TA-AuNP is also similar to those of AuNP(DTDTPA). The reaction of Ga3+ with TA-AuNP was performed under identical conditions as followed for the preparation of AuNP-(DTDTPA)(Ga). Final product was thoroughly characterized by HR-TEM, EDX, UV~ Visible, size and zeta analysis and data were compared with those of AuNP-(DTDTPA)(Ga).
[0067] Reaction of AuNP-PEG with Ga(N03)3-(AuNP-PEG+Ga): Gai XO.O ;
dissolved in water was added to AuNP-PEG (10.05 M [Au]) in different molar ratios (Au:Ga ratio; 1 :5, 1 :2.5, 1 : 1.125) and stirred for 3 hours at room temperature. Gold mirror formation was observed on the walls (ES-Figure 17) within 5 minutes of gallium nitrate addition at all ratios. The solution was centrifuged (20,000 rcf for 20 min) after 3 hours and pellets obtained were washed three times, resuspended in DI water and used for characterization.
[0068] Reaction of TA- AuNP with Ga(N03)3-(TA-AuNP÷Ga): Ga(NG3)3 dissolved in water was added to T A- AuNP (6.7 M [Au]) in 1 :5 (Au:Ga) molar ratio and after 30 minutes of addition, precipitate formation was observed and stirring was continued for 3 additional hours at room temperature. The solution was centrifuged (20,000 rcf for 20min) to obtain pellet and subsequently washed three times with DI water. The pellet obtained was resuspended in 0.01M NaOH and used for characterization.
[0069] HR-TEM images obtained for AiiNP-PEG+Ga pellet (Au:Ga, 1 :5) were not significantly different from those of AuNP-PEG except that larger size nanoparticles were observed. The formation of larger size nanoparticles
resulted due to the aggregation induced by addition of Ga(N03)3. With respect to TA-AuNP+Ga reaction, the final pellet did not show any change in size and distribution of the particles.
[0070] The EDX spectra of pellets obtained by addition of gallium nitrate to (AuNP- PEG (Au:Ga; 1 :5) and (TA-AuNP (Au:Ga; 1 :5) were recorded. Point and shoot technique was used to scan individual nanoparticles and the surrounding area. Scanning was performed additionally throughout the grid including dense nanoparticle regions. If any gallium were to be adhered to the surface of gold nanoparticle, then gallium signals would appear correspondingly. The absence of Ga k signal at 9.25 in pellets (AuNP- PEG+Ga ( 1 :5)) and (TA-Au P÷Ga (1 :5)), clearly indicating that there is no affinity between gold nanoparticles and gallium ions,
[0071 ] The experimental results presented unambiguously validate that Ga ions do not attach on the surface of gold nanoparticles. STEM-HAADF imase data and HR-TEM-EDX analysis of AuNP-(DTDTPA)(Ga) indicated that at point C>2, which is located in between gold cores (away from the gold surface), we detect the presence of Ga as well as a high carbon and oxygen content. This result is an independent proof that Ga3+ is chelated by DTDTPA, while conventional belief is that direct interactions of Au and Ga, are feasible only at high temperature (300-400°C). Our analytical data for AuNP- (DTDTPA)(Ga) and results from "model" nanoparticles confirm that Ga ions are not bound on the surface of gold nanoparticles.
[0072] FIG. 7 summarizes preferred synthesis. In phase 1 to phase 2, the AuNP- (DTDTPA)(Ga) is formed at room temperature. HRP is attached as a biomolecule model.
EXAMPLE 1.
[0073] By determination of the amount of Au by AAS and the amount of Ga by ICP- OES, the inventors have calculated that the maximum molar ratio Ga:Au that
can be obtained is -1.2, which means that there is slightly more Ga in the AuNPs than Au. This is actually a plausible result if one takes into account that the Au cores are very small (3-5 nm) and the polymeric coating of DTDTPAs can coordinate considerable amount of Ga. The zeta potential value of 2 (-81 mV (1) to -55 mV) shows a positive shift indicating coordination of electropositi e gallium coordination.
In order to investigate the maximum concentration of gallium that can be incorporated within the nanoconstruct (1) the inventors performed serial titrations of 1 with Ga3+ and evaluated the resultant conj gate using both Ga~ 71 NMR spectroscopy and 1CP-OES analysis (See Fig. 3). The NMR active 71 Ga is used as a probe to determine the concentration of chelated Ga. NMR. of different concentrations of Ga(N03 )3 were recorded in D20 (See Table 3). A standard curve using concentrations of non-chelated Ga vs. peak integration values were plotted. Using the plot, the inventors determined that 1 1 mM of Au can irreversibly chelate up to 58 mM of Ga. That indicates any gallium added beyond this concentration would not be chelated with AuNP- DTDTPA. The NMR results were validated by performing additional experiments using 1CP-OES. In this experiment, the inventors monitored Au/Ga ratios of the resultant conjugates after treatment of 1.1 mM of 1 (Au) with different amounts of Ga3+. Au/Ga ratio becomes a constant after addition of 58 mM of Ga3+. By these experiments, the inventors have demonstrated the exact concentration of Ga that can be irreversibly chelated to 1.
Table 3. Titration of GaCNOs with 1 and the amount of Ga3÷ detected by ICP-OES and ''Ga-NMR in terms of Au/Ga, ratio and Ga3+ in me respectively.
[0075] Synthesis of [AuNP(DTDTPA)(Peptide)] was conducted as described below.
The following peptides were used.
[0076] Peptide 1 Thioctic acid bombesin; Lipoic-Gln-Trp-Aia-Val-Gly-His-Leu-
Met-NH2 (Lipoic-QWAVGHLM~NH2)
[0077] Peptide 2 = ΤηϊοοΙγ1-£γ5-£γ8^γ8(ΟΟΤΑ)-ΡΕ02-Τγτ-ΗΪ8-Τφ-ΤγΓ-01γ-
Tyr-T nr-Pro-Gln-Asn-Val-Ile [Thioctyl-K (DOTA.)-PEG2-
YHWYGYTPQNVI]
[0078] Genera] procedure:
[0079] Thioctic acid terminated peptide was reacted with gold nanoparticles with stiochiometric ratios of AiuPeptide 1 :0.25, 1 :0.5, 1 : 1, 1 :2 and 1 :4. Typically, in a 20 ml glass vial, a solution of AuNP-DTDTPA ([Au]=2.28 μιηοΐ) using aqueous/methanolic mixture ( 1 :9) of 0.01M NaOH was prepared. Thioctic acid terminated peptide [0.57 LimoL 1 .14 μηιοΐ, 2.27 μτηοΐ, 4.54 μ ηοΐ and 9.08 μηιοΐ] were dissolved in 4 ml, of MeOH and then added to the nanoparticles solution. The reaction mixture was stirred for 2 hours at room temperature and formation of a dark brown precipitate was observed. The mixture was centrifuged (9300 g for 10 min at 20°C) and the supernatant was removed. The precipitated AuNPs were washed two times with MeOH and three times with water. The AuNP(DTDTPA)(Pe tide) were dried at low pressure and stored at -20°C.
[0080] Synthesis of AuNP(DTDTP A)(Ga)(Peptide) was conducted as follows.
[0081] Complexation with Gallium was performed by the addition of Ga(N03)3 to a colloidal solution of AuNP(DTDTPA)(Peptide) at room temperature with continuous stirring. The optimum content of gallium required for chelation was monitored by titrimetric analysis performed on ICP-OES and by 71Ga- NMR experiments. Typically, a solution of AuNP(DTDTPA)(Peptide) ([Au] = 22mM) was prepared using 0.0 IM NaOH to maintain the pH between 7 and 8. To this solution were added 118 mM of Ga(N03)3 with continuous stirring at room temperature, The formation of precipitate was immediately observed. The reaction mixture was allowed to stir for 3 hours and a brownish black residue was collected by centrifugation. The residue was washed with Dl water thoroughly to remove any imreacted gallium salt,
[0082] Synthesis of AuNP(DTDTPA)(67Ga)(Peptide) as performed as follows.
[0083] In a 2 mL eppendorf, 190 μΤ of 0.4M ammonium acetate (pH~7) were mixed with 20 (LtL of AuNP(DTDTPA)(Peptide) (5 mg/mL, 0.0 IM NaOH). To this mixture, 250 p,L of 67GaC13 (in 0.1M HCl) were added. The solution was left at room temperature for 5 min. The solution was then filtered in a Millipore Amicon Ultra 0,5 mL 10k. The collected AuNPs were diluted in 150 LiL of H20 and their radiochemical purity assessed by ITLC-SG, using 6M HCl/MeOH (5:95) as eluent (AuNP(DTDTPA)(Peptide): Rf 0). The radiolabeling yield was 87,5% and the radiochemical purity >95%,
[0084] Synthesis of 67Ga-AuNP-DTDTPA was performed as follows. In a 2 mL eppendorf, 350 μL of 0.4 VI ammonium acetate (pH~7) were mixed with 20 ,uL of Au P-DTDTP A iSmg/mL, [Au]= 11.42 μιηοΐ) in 0.01M NaOH). To this mixture, 250 μΤ of 67GaC13 (0.1M HCl) were added. The reaction mixture was heated at 85°C for 15 min. The solution was then filtered in a Millipore Amicon Ultra 0.5 mL 10k. The collected AuNPs were diluted in 150 μΐ, of H20 and their radiochemical purity assessed by ITLC-SG, using
6M HCl/MeOH (5 :95) as eluent (67Ga-AuNP-DTDTPA: Rf = 0). The radiolaheling yield was 86.7% and the radiochemical purity >95%. Physicochemical properties of the nanoconstnicts were then studied. Fig. 8 is a micrograph of (a) AuNP(DTDTPA)(Peptide) and (h) Au P(DTDTPA)(Ga)(Peptide). Table 4 below provides physicochemical properties of various reactions of BB -AuNP-DTDTPA.
Table 4: Physicochemical properties of various reactions of BBN-AuNP- DTDTPA.
[0086] Additional studies were conducted to evaluate in vitro stability of
Au P(DTDTPA)(Peptide) and A.uNPiDTDTPA)(Ga)(Pep†ide). These results are presented in Fig. 9.
[0087] Fig. 10 provides the XPS survey spectrum of AuNP(DTDTPA)(Peptide 1 ).
[0088] Fig. 1 1 provides the XPS hi-res spectrum of A.u P(DTDTPA)(Peptidel).
[0089] Table 5 reports the relative elemental composition for
AuNP(DTDTPA)iPeptide l)
"able 5; Relative Elemental Composition of AuDTBBN-NPs as Determined by GPS [Atom %]
C N O Na† Si* S Au Au P(DTDTP A)(Peptide 1 ) 57 14 19 3.0 1.2 3.1 3.6
† Sodium detected due to dissolution in aOH solution
* Silicon detected due to deposition on silicon wafer
90] Table 6 report relative compositions and most probable peak assignments for carbon species.
Table 6; Relative Compositions and Most Probable Peak Assignments for Carbon Species as Determined by XPS, C Is Region [Atom %]
C-C, C-O, C- 0-C=0, N-
C-H N C=0
AuNP(DTDTPA)(Peptide 1 ) 41 35 24
As shown in Fig. 11 , the analysis of the XPS hi-res spectrum for the S 2p region suggests that there are two different S states for the sample. The energies for elemental S, and some organic forms of S fall in the range of 163-164eV [ 1], which corresponds to the 163.2eV peak energy listed as Specie 2. This is likely S that is NOT bound to the Au. There is also a S peak (Specie 1) at 162.3eV, which corresponds to the peak energy reported for S-Au bonding [2]. The peak energy of 84.3eV for the Au 417 2 peak labeled Specie 2 suggests that the Au is bound to S [ 1], though this energ)^ is slightly lower than the tabulated value. If not for the evidence of Au-S bonding from the S 2p hi-res it might be believed that this peak was due to Au-N [3]. The sample also contains a peak at S3.6eV, which is likely due to Au in the metallic form, not bound with the organic material in any manner.
[0092] A dose dependent cytotoxisity assay with AuNP(DTDTPA)(Pe tide 1) was also conducted in PC-3 prostate cancer cells. The results of this assay are reported in Fig. 12.
[0093] While specific embodiments of the present invention have been shown and described, it should be understood that other modifications, substitutions and alternatives are apparent to one of ordinary skill in the art. Such modifications, substitutions and alternatives can be made without departing from the spirit and scope of the invention, which should be determined from the appended claims.
[0094] Various features of the invention are set forth in the appended claims.
Claims
1. A multi component nanomaterial, comprising at least one of the following nanoconstruct: AuNP(DTDTPA)(Ga), AuNP(DTDTPA)(biomolecule) and AuNP(DTDTPA)(Ga)(biomolecule), where DTDTPA is an amino-carboxylate ligand (diethvlene triamine pentaacetic acid, DTP A) linked to the surface of the Au nanoparticle (NP) via ditliiol (DT) linkage, and the biomolec le is selected from the group consisting of a peptide, antibody, ScFv antibody, the Fab portion of an antibody, affihody, enzyme, protein and a molecule comprising an amine group,
2. The nanomaterial of claim 1, comprising AuNP(DTDTPA)(Ga)(biomolecule).
3. The nanomaterial of claim 2, wherein the ratio of Au:Ga is in the range from 1 :5 to 1 : 1.125
4. The nanomaterial of claim 3, wherein the ratio of Au:Ga is 1 :5.
5. The nanomaterial of claim 2 in solution in a concentration in a range of 30 μ^/τη to 5 mg/ml with a pH in a range of 6 to 13.
6. The nanomaterial of claim 1 in solution in a concentration in a range of 30 μ^/τη to 5 mg/ml with a pH in a range of 6 to 13.
7. The nanomaterial of claim 1 , AuNP(DTDTPA)(Ga)(biomolecule), wherein the Ga comprises Ga
8. The nanomaterial of claim 1 , comprising AuNP(DTDTPA)(Ga)(biomolecule), wherein the Ga comprises Ga-68.
9, A method for synthesis of a multicornponent nanomaterial, the method comprising:
mixing an aqueous solution of one of the following: a biomolecule or Ga(N03)3 with AuNP(DTDTPA) conjugate dissolved in a buffer at room temperature and continually stirring the mixed solution for a predetermined time period until lormation of AuNP-(DTDTPA)(Ga) or AuNP(DTDTPA)(biomolecule) and the biomolecule is selected from the group consisting of a peptide, antibody, ScFv antibody, the Fab portion of an antibody, affibody, enzyme, protein and a molecule comprising an amine group.
10. The method of claim. 9, wherein the aqueous solution comprises Ga(N03)3, the method further comprises mixing with a biomolecule solution in buffer to form a conjugate of AuNP-(DTDTPA)(Ga) with the biomolecule.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LTEP14876059.8T LT3089997T (en) | 2013-12-30 | 2014-12-23 | Au MULTICOMPONENT NANOMATERIALS AND SYNTHESIS METHODS |
ES14876059T ES2796053T3 (en) | 2013-12-30 | 2014-12-23 | Au multicomponent nanomaterials and synthesis methods |
EP14876059.8A EP3089997B1 (en) | 2013-12-30 | 2014-12-23 | Au multicomponent nanomaterials and synthesis methods |
US15/109,058 US10317400B2 (en) | 2013-12-30 | 2014-12-23 | AU multicomponent nanomaterials and synthesis methods |
PL14876059T PL3089997T3 (en) | 2013-12-30 | 2014-12-23 | Au multicomponent nanomaterials and synthesis methods |
DK14876059.8T DK3089997T3 (en) | 2013-12-30 | 2014-12-23 | AU MULTICOM COMPONENT NANOMATERIALS AND PROCEDURES FOR SYNTHESIS |
RS20200657A RS60520B1 (en) | 2013-12-30 | 2014-12-23 | Au multicomponent nanomaterials and synthesis methods |
SI201431581T SI3089997T1 (en) | 2013-12-30 | 2014-12-23 | Au multicomponent nanomaterials and synthesis methods |
US16/228,178 US10914734B2 (en) | 2013-12-30 | 2018-12-20 | AU multicomponent nanomaterials and synthesis methods |
HRP20200905TT HRP20200905T1 (en) | 2013-12-30 | 2020-06-05 | Au multicomponent nanomaterials and synthesis methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361964285P | 2013-12-30 | 2013-12-30 | |
US61/964,285 | 2013-12-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/109,058 A-371-Of-International US10317400B2 (en) | 2013-12-30 | 2014-12-23 | AU multicomponent nanomaterials and synthesis methods |
US16/228,178 Continuation US10914734B2 (en) | 2013-12-30 | 2018-12-20 | AU multicomponent nanomaterials and synthesis methods |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015103028A1 true WO2015103028A1 (en) | 2015-07-09 |
Family
ID=53493924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/072092 WO2015103028A1 (en) | 2013-12-30 | 2014-12-23 | Au multicomponent nanomaterials and synthesis methods |
Country Status (12)
Country | Link |
---|---|
US (2) | US10317400B2 (en) |
EP (1) | EP3089997B1 (en) |
DK (1) | DK3089997T3 (en) |
ES (1) | ES2796053T3 (en) |
HR (1) | HRP20200905T1 (en) |
HU (1) | HUE050462T2 (en) |
LT (1) | LT3089997T (en) |
PL (1) | PL3089997T3 (en) |
PT (1) | PT3089997T (en) |
RS (1) | RS60520B1 (en) |
SI (1) | SI3089997T1 (en) |
WO (1) | WO2015103028A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018129501A1 (en) * | 2017-01-09 | 2018-07-12 | The Curators Of The University Of Missouri | Targeted doxorubicin-gold nanoconjugates for tumor therapy |
WO2020193526A1 (en) | 2019-03-25 | 2020-10-01 | Sphera Technology Gmbh | Multicomponent system and process for producing a multicomponent system, especially for use in microelectronics |
DE102020124955A1 (en) | 2020-09-24 | 2022-03-24 | Sphera Technology Gmbh | Electronic unit with an integrated circuit and method for its production |
RU2773707C2 (en) * | 2017-01-09 | 2022-06-08 | Зе Кураторс Оф Зе Юниверсити Оф Миссури Сша | Doxorubicin-gold nanoconjugates with directional influence for tumor therapy |
WO2023242766A1 (en) | 2022-06-15 | 2023-12-21 | Alembic Pharmaceuticals Limited | Gold nanoconjugates |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3089997T (en) * | 2013-12-30 | 2020-07-10 | The Curators Of The University Of Missouri | Au MULTICOMPONENT NANOMATERIALS AND SYNTHESIS METHODS |
WO2023224898A1 (en) * | 2022-05-17 | 2023-11-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Seedless synthesis of anisotropic gold nanoflowers for cellular control and drug delivery applications |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222595A1 (en) | 2005-03-31 | 2006-10-05 | Priyabrata Mukherjee | Nanoparticles for therapeutic and diagnostic applications |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009005752A1 (en) * | 2007-06-28 | 2009-01-08 | The Curators Of The University Of Missouri | Stabilized gold nanoparticle and contrast agent |
GB201009455D0 (en) * | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
EP2828283B1 (en) * | 2012-03-22 | 2018-04-18 | The Curators Of The University Of Missouri | Peptide with gold binding and egfr receptor affinity and same attached to gold nanostructure |
TW201511774A (en) * | 2013-09-18 | 2015-04-01 | Iner Aec Executive Yuan | Radiolabeled active targeting pharmaceutical composition and the use thereof |
LT3089997T (en) * | 2013-12-30 | 2020-07-10 | The Curators Of The University Of Missouri | Au MULTICOMPONENT NANOMATERIALS AND SYNTHESIS METHODS |
-
2014
- 2014-12-23 LT LTEP14876059.8T patent/LT3089997T/en unknown
- 2014-12-23 ES ES14876059T patent/ES2796053T3/en active Active
- 2014-12-23 HU HUE14876059A patent/HUE050462T2/en unknown
- 2014-12-23 DK DK14876059.8T patent/DK3089997T3/en active
- 2014-12-23 US US15/109,058 patent/US10317400B2/en active Active
- 2014-12-23 SI SI201431581T patent/SI3089997T1/en unknown
- 2014-12-23 PL PL14876059T patent/PL3089997T3/en unknown
- 2014-12-23 PT PT148760598T patent/PT3089997T/en unknown
- 2014-12-23 EP EP14876059.8A patent/EP3089997B1/en active Active
- 2014-12-23 WO PCT/US2014/072092 patent/WO2015103028A1/en active Application Filing
- 2014-12-23 RS RS20200657A patent/RS60520B1/en unknown
-
2018
- 2018-12-20 US US16/228,178 patent/US10914734B2/en active Active
-
2020
- 2020-06-05 HR HRP20200905TT patent/HRP20200905T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222595A1 (en) | 2005-03-31 | 2006-10-05 | Priyabrata Mukherjee | Nanoparticles for therapeutic and diagnostic applications |
Non-Patent Citations (12)
Title |
---|
CUTLER ET AL., WORLD JOURNAL OF NUCLEAR MEDICINE, vol. 12, no. 1, February 2013 (2013-02-01), pages 37 - 38 |
CUTLER ET AL.: "In Vivo Evaluation of Multifunctional DTDTPA Gold Nanoparticles for Molecular Imaging", WORLD JOURNAL OF NUCLEAR MEDICINE, vol. 12, no. SUPPL., 1 February 2013 (2013-02-01), pages 1 - 188, XP008184663 * |
DEBOUTTIERE ET AL., ADVANCED FUNCTIONAL MATERIALS, 2006, pages 2330 - 2339 |
DEBOUTTIERE ET AL.: "Design of Gold Nanoparticles for Magnetic Resonance Imaging", ADVANCED FUNCTIONAL MATERIALS, vol. 16, no. ISS. 1, 3 November 2006 (2006-11-03), pages 2330 - 2339, XP055355406 * |
MAECKE ET AL., J NUCL MED, 2005, pages 172S - 178S |
MAECKE ET AL.: "68Ga-Labeled Peptides in Tumor Imaging", THE JOURNAL OF NUCLEAR MEDICINE, vol. 46, no. 01, 1 January 2005 (2005-01-01), pages 172S - 178S, XP008092628 * |
See also references of EP3089997A4 * |
VALK P. ET AL: "Positron Emission Tomography: Basic Science and Clinical Practice. 3rd edition", 28 October 2004, SPRINGER, ISBN: 978-185233485, pages: 255, XP008184071 * |
YAZDANPANAH ET AL., APPL PHYS LETT, 2004, pages 1592 - 1594 |
YAZDANPANAH ET AL.: "Gallium-driven assembly of gold nanowire networks''.", APPLIED PHYSICAS LETTERS, vol. 85, no. 09, 30 August 2004 (2004-08-30), pages 1592 - 1594, XP012064369 * |
ZAMBRE ET AL., CHEM COMM, 2014, pages 3281 - 3284 |
ZAMBRE ET AL.: "Synthesis and characterization of functional multicomponent nanosized gallium chelated gold crystals", CHEMICAL COMMUNICATIONS, vol. 50, no. 25, 13 January 2014 (2014-01-13), pages 3281 - 3284, XP055355411 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018129501A1 (en) * | 2017-01-09 | 2018-07-12 | The Curators Of The University Of Missouri | Targeted doxorubicin-gold nanoconjugates for tumor therapy |
CN110178028A (en) * | 2017-01-09 | 2019-08-27 | 密苏里大学管理机构 | Targeting peptide-doxorubicin-gold nano conjugate for oncotherapy |
KR20190104333A (en) * | 2017-01-09 | 2019-09-09 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | Targeted Doxorubicin-Gold Nanoconjugates for Tumor Therapy |
JP2020504130A (en) * | 2017-01-09 | 2020-02-06 | ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ | Targeted doxorubicin-gold nanoconjugate for tumor therapy |
JP7017258B2 (en) | 2017-01-09 | 2022-02-08 | ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ | Targeted Doxorubicin-Gold Nanoconjugate for Tumor Treatment |
RU2773707C2 (en) * | 2017-01-09 | 2022-06-08 | Зе Кураторс Оф Зе Юниверсити Оф Миссури Сша | Doxorubicin-gold nanoconjugates with directional influence for tumor therapy |
AU2018205349B2 (en) * | 2017-01-09 | 2022-09-29 | The Curators Of The University Of Missouri | Targeted doxorubicin-gold nanoconjugates for tumor therapy |
KR102568577B1 (en) | 2017-01-09 | 2023-08-18 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | Targeted doxorubicin-gold nanoconjugates for tumor therapy |
WO2020193526A1 (en) | 2019-03-25 | 2020-10-01 | Sphera Technology Gmbh | Multicomponent system and process for producing a multicomponent system, especially for use in microelectronics |
DE102020124955A1 (en) | 2020-09-24 | 2022-03-24 | Sphera Technology Gmbh | Electronic unit with an integrated circuit and method for its production |
WO2022063977A2 (en) | 2020-09-24 | 2022-03-31 | Sphera Technology Gmbh | Electronics unit and method for the production thereof |
WO2023242766A1 (en) | 2022-06-15 | 2023-12-21 | Alembic Pharmaceuticals Limited | Gold nanoconjugates |
Also Published As
Publication number | Publication date |
---|---|
PT3089997T (en) | 2020-06-17 |
ES2796053T3 (en) | 2020-11-25 |
LT3089997T (en) | 2020-07-10 |
EP3089997A4 (en) | 2017-06-14 |
DK3089997T3 (en) | 2020-06-15 |
EP3089997B1 (en) | 2020-04-15 |
US20190187137A1 (en) | 2019-06-20 |
HUE050462T2 (en) | 2020-12-28 |
RS60520B1 (en) | 2020-08-31 |
SI3089997T1 (en) | 2020-08-31 |
HRP20200905T1 (en) | 2020-09-04 |
US10317400B2 (en) | 2019-06-11 |
US10914734B2 (en) | 2021-02-09 |
EP3089997A1 (en) | 2016-11-09 |
PL3089997T3 (en) | 2020-09-07 |
US20170168045A1 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10914734B2 (en) | AU multicomponent nanomaterials and synthesis methods | |
Mathew et al. | Noble metal clusters: applications in energy, environment, and biology | |
Zheng et al. | Overcoming bacterial physical defenses with molecule-like ultrasmall antimicrobial gold nanoclusters | |
Luo et al. | Engineering ultrasmall water-soluble gold and silver nanoclusters for biomedical applications | |
Wang et al. | Multivalent glyconanoparticles with enhanced affinity to the anti-viral lectin Cyanovirin-N | |
Warsi et al. | Gd-functionalised Au nanoparticles as targeted contrast agents in MRI: relaxivity enhancement by polyelectrolyte coating | |
CN110178028B (en) | Targeted doxorubicin-gold nanoconjugates for tumor therapy | |
Zhang et al. | Synthesis of sub-5 nm Au–Ag alloy nanoparticles using bio-reducing agent in aqueous solution | |
JP5873719B2 (en) | Conjugates containing platinum-containing compound-coated nanoparticles | |
Saleh et al. | Cucurbiturils in drug delivery and for biomedical applications | |
Damle et al. | Modulating pro-and antioxidant activities of nanoengineered cerium dioxide nanoparticles against Escherichia coli | |
Somaskandan et al. | Surface protected and modified iron based core-shell nanoparticles for biological applications | |
Al Shehab et al. | Curcumin mediated PEG thiol acid conjugated gold nanoparticles for the determination of melamine | |
Zhang et al. | Kinetics‐Controlled Formation of Gold Clusters Using a Quasi‐Biological System | |
Nikitina et al. | The first heterometallic Cu (II)/Cr (III) complex with an open-chain Schiff-base ligand self-assembled from copper powder, Reineckes salt, ethylendiamine and acetone | |
Matassini et al. | Gold nanoparticles are suitable cores for building tunable iminosugar multivalency | |
Oliva et al. | Solvent-assisted in situ synthesis of cysteamine-capped silver nanoparticles | |
EP3865477B1 (en) | Carbene compound, carbene-metal nanoparticle complex and preparation method thereof | |
JPWO2009031714A1 (en) | Solvent dispersible particles | |
Annušová et al. | Selective Tumor Hypoxia Targeting Using M75 Antibody Conjugated Photothermally Active MoO x Nanoparticles | |
Zambre et al. | Synthesis and characterization of functional multicomponent nanosized gallium chelated gold crystals | |
Uddin et al. | Novel green hemoglobin-mediated biosynthesis of gold nanoparticles | |
Sun et al. | A Stepwise-Confined Self-Reduction Strategy to Construct a Dynamic Nanocatalyst for Boosting Tumor Catalytic Therapy | |
Karimi Shervedani et al. | Nanobioconjugated system formed of folic acid–deferrioxamine–Ga (III) on gold surface: Preparation, characterization, and activities for capturing of mouse breast cancer cells 4T1 | |
Bian et al. | A seedless, surfactant-free synthesis of gold nanospheres, nanosheets, and nanostars based on functionalized tryptophan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14876059 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15109058 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014876059 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014876059 Country of ref document: EP |